Where Does the FDA Stand on CBD?

Want to know where the FDA stands on CBD? Check out “What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD.”

In the update, the FDA reiterates its current views about regulation of cannabis products. While the agency acknowledges the tremendous interest in these products, it stresses that many of its scientific and medicinal properties are still unknown. Importantly, the FDA identifies the following issues of concern:

The effects CBD could cause in the body, such as toxicity to the liver, when someone ingests CBD regularly over a long period of time.

The cumulative exposure to CBD if people access it across a broad range of consumer products.

* The effects of CBD on special populations (e.g., the elderly, children, adolescents, pregnant and lactating women) or types of animals (e.g., species, breed, or class).

* The safety of CBD use in animals (e.g., species, breed, or class), including pets.

* The update also once again stresses FDA’s position that the agency will prioritize public health concerns and take enforcement action against manufacturers of CBD products that make claims to prevent, diagnose, or treat diseases. The Update further notes that FDA is also investigating reports of CBD potentially containing contaminants such as pesticides.

* The FDA is continuing to evaluate the regulatory framework for cannabis products and is currently gathering information through its request to stakeholders to submit to the public docket with a deadline of July 2, 2019. Interested stakeholders are encouraged to submit their views to the FDA docket. 

The agency held a public hearing on May 31, and has a high-level task force working through the various issues. It is expected they will make a recommendation about any possible changes to FDA regulations by late summer.

Facebook
Twitter
Pinterest
Print
Email

Recent Articles

Upcoming Legislative Sessions: What can we expect to see?

In my last article I discussed the 2022 legislative sessions in many states. In this article I want to shed some light on what we and many other advocates across the country anticipate in the 2023 session. As always, if you have any questions about how to get involved, ideas and relationships you may have

Read More »

How to Attract Seasonal Help

If you’re struggling to find seasonal workers, you’re not alone. A recent survey found that a quarter of small business owners have had a harder time finding seasonal help this year than in the past. And given that the clock’s ticking down, you might be growing increasingly desperate to find temporary workers. Offering minimal wages

Read More »

Cannabis Banking Bill Could Pass Congress by Year’s End

It has been a long road for the cannabis banking bill that aims to protect financial institutions that work with the marijuana industry. But analysts say the “SAFE Banking Plus,” has a roughly 70% chance of passing before the end of 2022. The House passed the SAFE Banking Act in 2021 and 2019, but getting

Read More »

TPE23: The Ultimate Destination for Independent Retailers

Tobacco Plus Expo is bigger and better. And while they’re still using the acronym TPE, those letters now stand for Total Product Expo. For 2023, TPE, held at the Las Vegas Convention Center, February 22-24, will see its show floor grow by 30 percent to 166,000 square feet. The annual exhibition has evolved to include

Read More »

Claims of ‘Fentanyl-Laced Cannabis’ Are Common, But Are They Accurate?

By Paul Armentano Rarely a week goes by without police or other public officials warning about so-called “fentanyl-laced” weed. Upon closer inspection, however, there’s little if any truth behind these sensational claims. A case in point: Police in Brattleboro, Vermont generated headlines last year when they, along with agents from the federal Drug Enforcement Administration

Read More »

Social Media

Most Recent

Are you 18 or older?